Exhibit 99.1 Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results • Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling program • Completed patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in the first half of 2025 • $37.8 million in cash, cash equivalents and money market funds as of December 31, 2023, with a cash runway through first quarter 2025 • Management to host conferenc ...